Bazedoxifene is a non-steroidal, orally active selective estrogen receptor modulator that exhibits activity against ERalpha and ERbeta with IC50 values of 26 nM and 99 nM, respectively. Bazedoxifene also inhibits IL-6/GP130 protein interactions. Bazedoxifene is utilized in research on postmenopausal osteoporosis and pancreatic cancer, serving as a dual-purpose compound for hormonal and cytokine pathway investigations.
